Inflammatory cytokine

Medicines360 and DKT WomanCare Announce Strategic Partnership to Expand Access to the Hormonal IUD Avibela™

Retrieved on: 
Wednesday, January 31, 2024
SAN, Nausea, Clinical trial, Perforation, Birth, Fibroid, Internal bleeding, Liver failure, Infection, Artery, Pelvic pain, DKT International, Jaundice, Anticoagulant, Blood pressure, Ovarian cyst, Woman, Acne, Organization, Partnership, Endometritis, Angioedema, History, Abscess, Contraindication, DKT, Peritonitis, Rash, Coagulopathy, Dyspareunia, Inflammatory cytokine, Adhesion, Vomiting, Bacterial vaginosis, Headache, Bowel obstruction, IUS, Uterus, STI, Breast cancer, Miscarriage, Patient, Fertility, Sepsis, Marketing, Risk, Stroke, Organ, Streptococcus, Hormone-sensitive cancer, Liver tumor, Cyst, Intrauterine device, GAS, Pregnancy, PID, Social marketing, Vaginitis, Migraine, Myocardial infarction, Health, Brain, Birth control

"As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.

Key Points: 
  • "As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.
  • “DKT WomanCare looks forward to leveraging our global partnerships and commercial relationships to ensure every woman, regardless of income, can access affordable, high-quality contraception.
  • As the supplier of AVIBELA, Medicines360 will focus on providing quality assurance and regulatory oversight, as well as ensuring sustainable product supply to DKT WomanCare and global procurement agencies.
  • Together, Medicines360 and DKT WomanCare will meet the growing demand for quality-assured, affordable hormonal IUDs and help build a robust and sustainable global contraceptive market.

Philogen Announces R&D Program Update

Retrieved on: 
Friday, July 2, 2021
Branches of biology, Medical specialties, Clinical medicine, Cytokines, Immunology, Inflammatory cytokine, Clusters of differentiation, Cytokine, Tumor necrosis factor, Immunotherapy, E-selectin, L19

A full pipeline update will be made to the market on 28 September, 2021, in the Companys Half Year results announcement.

Key Points: 
  • A full pipeline update will be made to the market on 28 September, 2021, in the Companys Half Year results announcement.
  • Fibromun (L19TNF), wholly-owned by Philogen, is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine).
  • The results from these studies will provide the basis for a pivotal clinical program in selected cancer types.
  • Philogen accepts no responsibility for the data protection policy and customer information of websites of third parties and shall not be liable for the content or web pages of third parties which are linked to the Philogen website, or which display the Philogen website in frames.

New Study: Eating Prunes Daily Improves Risk Factors for Heart Disease and Inflammation in Postmenopausal Women

Retrieved on: 
Tuesday, June 22, 2021
Medical specialties, Branches of biology, Immunology, Cytokines, Clinical medicine, Cardiovascular disease, Inflammatory cytokine, Inflammation, Cytokine, Tumor necrosis factor, Oxygen radical absorbance capacity

ROSEVILLE, Calif., June 22, 2021 /PRNewswire/ --New research published in the Journal of Medicinal Food suggests eating prunes each day can improve risk factors for cardiovascular disease (CVD) including raising antioxidant capacity and reducing inflammation among healthy, postmenopausal women.

Key Points: 
  • ROSEVILLE, Calif., June 22, 2021 /PRNewswire/ --New research published in the Journal of Medicinal Food suggests eating prunes each day can improve risk factors for cardiovascular disease (CVD) including raising antioxidant capacity and reducing inflammation among healthy, postmenopausal women.
  • The research led by San Diego State University reveals that prunes can positively affect heart disease risk.
  • Eating prunes daily also promoted higher antioxidant capacity and lowered levels of the inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha associated with CVD risk.
  • Notably, body mass index and weight of the study participants were maintained during the trial despite adding prunes to the usual diet.

New data presented at Virtual EULAR 2021 Congress by AKL Research and Development demonstrate its investigational osteoarthritis drug APPA reduces senescence and reactive oxygen species production

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Biology, Medical specialties, Skeletal disorders, Senescence, Arthritis, Cellular processes, Cellular senescence, Senescence-associated secretory phenotype, Chondrocyte, Autophagy, Inflammatory cytokine

Findings from the study indicate its investigational oral osteoarthritis (OA) drug APPA can reduce reactive oxygen species (ROS) production and senescence of human articular chondrocytes, both indicators associated with OA pathogenesis.

Key Points: 
  • Findings from the study indicate its investigational oral osteoarthritis (OA) drug APPA can reduce reactive oxygen species (ROS) production and senescence of human articular chondrocytes, both indicators associated with OA pathogenesis.
  • In chondrocytes, senescence-associated secretory phenotype factors, such as pro-inflammatory cytokines and extracellular matrix degrading enzymes, can contribute to the development and progression of OA[2][3].
  • This research builds on previous work from INBIC and other laboratories that showed APPA modifies a number of pathways involved in the development of OA.
  • [3]Benderdour M, Martel-Pelletier J, Pelletier JP, Kapoor M, Zunzunegui MV, Fahmi H. Cellular Aging, Senescence and Autophagy Processes in Osteoarthritis.

New data presented at Virtual EULAR 2021 Congress by AKL Research and Development demonstrate its investigational osteoarthritis drug APPA reduces senescence and reactive oxygen species production

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Biology, Medical specialties, Skeletal disorders, Senescence, Arthritis, Cellular processes, Cellular senescence, Senescence-associated secretory phenotype, Chondrocyte, Autophagy, Inflammatory cytokine

Findings from the study indicate its investigational oral osteoarthritis (OA) drug APPA can reduce reactive oxygen species (ROS) production and senescence of human articular chondrocytes, both indicators associated with OA pathogenesis.

Key Points: 
  • Findings from the study indicate its investigational oral osteoarthritis (OA) drug APPA can reduce reactive oxygen species (ROS) production and senescence of human articular chondrocytes, both indicators associated with OA pathogenesis.
  • In chondrocytes, senescence-associated secretory phenotype factors, such as pro-inflammatory cytokines and extracellular matrix degrading enzymes, can contribute to the development and progression of OA[2][3].
  • This research builds on previous work from INBIC and other laboratories that showed APPA modifies a number of pathways involved in the development of OA.
  • [3]Benderdour M, Martel-Pelletier J, Pelletier JP, Kapoor M, Zunzunegui MV, Fahmi H. Cellular Aging, Senescence and Autophagy Processes in Osteoarthritis.

Xalud Therapeutics’ Lead Candidate, XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas

Retrieved on: 
Thursday, May 20, 2021
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Medical specialties, Biology, Immunology, Cytokines, Molecular biology, Animal physiology, Human physiology, Inflammation, Cytokine, Inflammatory cytokine, Plasmid, XT-150, Xalud Therapeutics, XT-150, XALUD THERAPEUTICS

XT-150 is a locally injectable, plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of the cytokine IL-10, to address pathologic inflammation and pain.

Key Points: 
  • XT-150 is a locally injectable, plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of the cytokine IL-10, to address pathologic inflammation and pain.
  • \xe2\x80\x9cThrough localized delivery of IL-10v, we believe XT-150 may have a large-scale impact in reducing inflammation at several somatic and neurologic targets.
  • XT-150 uses a non-integrating therapeutic plasmid DNA that enables local delivery of IL-10v directly to the site of inflammation.
  • IL-10 is a potent anti-inflammatory cytokine that plays a critical role in maintaining homeostasis and reducing inflammation.

MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board

Retrieved on: 
Monday, May 17, 2021
Health, Pharmaceutical, Medical specialties, Clinical medicine, Branches of biology, Immunology, Cytokines, Inflammatory cytokine, Tumor necrosis factor, Cytokine, Sjögren syndrome, Inflammation

degree in medical and scientific illustration from the University of Michigan in 1989.

Key Points: 
  • degree in medical and scientific illustration from the University of Michigan in 1989.
  • MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.
  • MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-\xce\xb1 blocking drugs, and aging and longevity.
  • Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements.

MyMD Pharmaceuticals Schedules Business Update Conference Call

Retrieved on: 
Wednesday, May 12, 2021
Health, Pharmaceutical, Medical specialties, Branches of biology, Immunology, Cytokines, Clinical medicine, Inflammatory cytokine, Tumor necrosis factor, Cytokine, Inflammation

MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.

Key Points: 
  • MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.
  • MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-\xce\xb1 blocking drugs, and aging and longevity.
  • Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements.
  • A discussion of these and other factors with respect to MyMD is set forth in the registration statement on Form S-4 filed by MyMD on January 15, 2021, as amended.

Connect Biopharma Announces First Patient Dosed in Phase 2 Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Persistent Asthma

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Medical specialties, Biology, Interleukins, Cell biology, Cytokines, Immune system, Lymphatic system, T helper cell, Inflammatory cytokine, Cytokine

Many patients with moderate-to-severe asthma continue to have unmet need and could benefit from additional treatment options,\xe2\x80\x9d said Zheng Wei, PhD, Co-founder and CEO of Connect Biopharma.

Key Points: 
  • Many patients with moderate-to-severe asthma continue to have unmet need and could benefit from additional treatment options,\xe2\x80\x9d said Zheng Wei, PhD, Co-founder and CEO of Connect Biopharma.
  • Type 2 inflammation is mediated by type 2 helper T-cells (TH2), which secrete inflammatory cytokines including IL-3, IL-4, L-5, IL-9 and IL-13.
  • The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its plans will be achieved.
  • This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\n'

MyMD Pharmaceuticals Begins Trading on Nasdaq

Retrieved on: 
Monday, April 19, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Branches of biology, Immunology, Cytokines, Clinical medicine, Inflammatory cytokine, Tumor necrosis factor, Cytokine, Inflammation

MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.

Key Points: 
  • MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.
  • MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-\xce\xb1 blocking drugs, and aging and longevity.
  • Forward-looking statements speak only as of the date they are made and none of MYMD nor its affiliates assume any duty to update forward-looking statements.
  • A discussion of these and other factors with respect to MYMD is set forth in the registration statement on Form S-4 filed by MYMD on January 15, 2021, as amended.